Inclusion Criteria:  Able to provide informed written consent Able to withhold use of other chamomile products (teas, lotions, supplements, extracts); will only use study-supplied chamomile products.  Exclusion Criteria:  Past medical/family history of bleeding/thrombotic disorders (e.g. hemophilia, von-Willebrand disease) Chronic medications known to affect hemostasis (anticoagulants, antiplatelet agents, SSRIs, herbal/complementary medicine agents) Three or more alcoholic drinks daily Sedentary status/ restricted mobility Active smoker or quit smoking within one week of screening Females who are pregnant, breast-feeding, or lactating Scheduled surgical procedure during study period Hospitalized patients Underweight (BMI < 18 kg/m2) or history of malnourishment Active symptoms of a respiratory, dermatologic, urinary, or gastrointestinal infection Diagnosed allergy to chamomile Severe allergy to ragweed Physical inability to consume chamomile tea according to the study dosing schedule Prescription usage of an anticoagulant agent such as warfarin, anti-Xa inhibitor, or other novel oral anticoagulants ADP antagonist use, including clopidogrel, prasugrel, and ticagrelor GPIIb/IIIa inhibitor use, including ticlopidine, eptifibatide More than weekly NSAID use (e.g. aspirin, ibuprofen, naproxen) Diagnosis of a bleeding-diathesis disorder Diagnosis of a hypercoagulable state History of elevated INR (including baseline study) or other abnormal bleeding study (PT, aPTT, thrombin time, reptilase time, above the upper limit of normal for Stony Brook Hospital Reference Range) while not taking anticoagulants or herbal supplements listed below  Active intake of the following herbal supplements at time of study enrollment that may alter baseline coagulation function including:  Ginger Garlic Gingko Ginseng Fish oil Black Cohosh Feverfew Valerian Coenzyme Q10 Goldenseal St. John Wort Baseline CBC with either a hematocrit below 30% or platelet count below 150,000, white blood cell count above 15,000 or less than 3,000. Inability to discontinue the aforementioned herbal supplements more than 14 days before enrollment into the study. History of estrogen-dependent condition such as uterine fibroids, breast cancer, uterine cancer, or ovarian cancer Significant fear of needles or fainting blood draws Actively taking cyclosporine Patient refusal to participate in study for the allotted study period